Know Cancer

or
forgot password

Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor


Phase 2
18 Years
N/A
Not Enrolling
Both
Neuroendocrine Tumor

Thank you

Trial Information

Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor


Inclusion Criteria:



- low to intermediate grade neuroendocrine tumor not amenable to surgery or local
therapy

Exclusion Criteria:

- poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

response rate

Outcome Time Frame:

1~2 year

Safety Issue:

Yes

Authority:

Korea: Food and Drug Administration

Study ID:

2009-09-090

NCT ID:

NCT01099540

Start Date:

April 2010

Completion Date:

March 2013

Related Keywords:

  • Neuroendocrine Tumor
  • neuroendocrine tumor
  • Neuroendocrine Tumors

Name

Location